ENDO in Medical Technology

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

BELLEVILLE, Ontario and CHADDS FORD, Pa., July 10 /PRNewswire-FirstCall/ -- Bioniche Life Sciences Inc. (TSX: BNC) and Endo Pharmaceuticals (Nasdaq: ENDP ) jointly announced today that Endo has licensed from Bioniche the exclusive rights to develop and market Urocidin(TM) in the U.S. with ...

Neurocrine Biosciences Presents Elagolix Data

...gton DC, June 10-13, 2009. The first clinical abstract presentation at endo 09 reviews the results of a Phase I study in which elagolix was evaluated o...among the placebo and elagolix groups. The second clinical abstract at endo 09 reports results from a Phase II study where the safety of elagolix was e...

Logical Therapeutics Appoints Peter A. Lankau as CEO and Director

...ny's Board of Directors. Mr. Lankau was most recently President and CEO of endo Pharmaceuticals Inc., a publicly traded specialty pharmaceutical company. ...ficant gastrointestinal risks." Mr. Lankau became President and CEO of endo Pharmaceuticals in 2005, after having served as President and COO since 200...

DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program

...a 74 patient Phase IIb clinical trial conducted by endo Pharmaceuticals of TRANSDUR(TM)-Sufentanil, a prop...fective August 26, 2009, we will receive back from endo Pharmaceuticals the right to develop and commercialize TRANSDUR-Sufentanil in the U.S. and Canada. endo has committed to assist us in an orderly and rapid...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

...ADDS FORD, Pa., March 12 /PRNewswire-FirstCall/ -- endo Pharmaceuticals (Nasdaq: ENDP ) and its majority...evus Pharmaceuticals, a majority interest in which endo acquired earlier this year. If approved, NEBIDO i...to approximately $675 million in 2007. About endo ...

Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments

...HADDS FORD, Pa., Feb. 10 /PRNewswire-FirstCall/ -- endo Pharmaceuticals (Nasdaq: ENDP ) announced today ... motor neurons. Under the terms of the agreement, endo will receive exclusive world-wide rights to the te...scovery and preclinical research activities, while endo will be responsible for all clinical development a...

Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration

...HADDS FORD, Pa., Jan. 29 /PRNewswire-FirstCall/ -- endo Pharmaceuticals (Nasdaq: ENDP ) announced today ... testing and will be returned to Alexza. In 2007, endo licensed exclusive rights to develop and commercia...g from our virtual discovery program." About endo ...

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

... Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press relea...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

... Product candidates that have completed Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. In addition, AZ-002 (Staccato alprazolam) has complet...

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

... Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releas...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

...entanyl). Alexza is jointly developing AZ-003 with endo Pharmaceuticals, Inc., or Endo, for the treatment of breakthrough pain. endo is responsible for regulatory, pre-clinical and cl...ment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Stac...

Focal Cryoablation Highlighted in Urology Times Best of AUA Orlando 2008

... Publication Highlights the Treatment's 'Low Rates of Morbidity' IRVINE, Calif., July 30 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: endo ), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologis...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

... Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releas...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

... Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releas...

New Subset Analysis of AndroGel(R) Data Highlights Efficacy - Regardless of BMI

...-label extension study was published that showed that AndroGel was safe for men to use over the long term. Study Highlights The study presented at endo examined the relationship between BMI and sex hormones in hypogonadal men both before and after treatment with testosterone. The study found: --...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

... Phase 2 testing. Product candidates in Phase 1 testing are AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releas...

Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder

...se 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releas...

Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer

...atients Whose Cancer Returns after Radiation IRVINE, Calif., June 6 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: endo ), an innovative medical device company providing minimally invasive technologies for tissue and tumor ablation, announced today that a group of the n...

Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting

...f Leading Cancer Centers Presenting Cryoablation Data IRVINE, Calif., May 21 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: endo ), an innovative medical device company focused on the development of minimally invasive technologies used by urologists and interventional radiologis...

Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting

...se 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releas...

Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients

...se 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releas...

Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)

...se 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releas...

Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status

...h our own programs, and with our partnerships with endo Pharmaceuticals and Symphony Allegro, we look forw...cember 2007, Alexza entered into an agreement with endo Pharmaceuticals to jointly develop AZ-003. endo is responsible for regulatory, pre-clinical and cl...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

...se 2 testing. Product candidates in Phase 1 testing include AZ-003 (Staccato fentanyl) for the treatment of breakthrough pain, which is partnered with endo Pharmaceuticals in North America, and AZ-007 (Staccato zaleplon) for the treatment of insomnia. More information, including this and past press releas...

Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status

...candidates, and with our product partnerships with endo Pharmaceuticals and Symphony Allegro, we look forw...ered into a license and development agreement with endo Pharmaceuticals Holdings Inc. for development ...t for clinical development and commercial supply. endo has primary responsibility for regulatory, pre...

Theratechnologies: TH9507 Phase 3 Clinical Update

... - Data from first Phase 3 trial presented at endo 2007 - Regulatory approvals for second Phase 3 trial open the door for p...erica and Europe suffer an excessive accumulation of visceral fat. About endo ENDO is the annual meeting of the Endocrine Society, and is the largest ...

Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

... as a potential method for regulating metabolism, decreasing body weight and managing blood glucose. The data were presented in poster sessions during endo 07, The Endocrine Society's 89th Annual Meeting, being held in Toronto, Canada. Elixir is focused on the development of drugs to treat and prevent met...

Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine

... 09, 2007 (MARKET WIRE via COMTEX News Network) -- endo Pharmaceuticals Inc., a wholly owned subsidiary of...nd 14 percent (twice daily) in the FROVA groups. endo has submitted a supplemental New Drug Application ... skeletal pain, chest pain, and dyspepsia. About endo A wholly owned subsidiary of...